Design Therapeutics, Inc. (DSGN)
$15.11-$0.14 (-0.92%) Today
David ShapiroDesign Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 6 | 180,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
10 Form 4 filings on record, the earliest from Dec 19, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Simeon George | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| John P. Schmid | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Rodney W. Lappe | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Justin D. Gover | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| David Shapiro | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Heather A. Berger | Grant or award | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| David Shapiro | Grant or award | Stock option (right to buy) | 60,000 | $0.00 | - | |
| David Shapiro | Grant or award | Stock option (right to buy) | 7,500 | $0.00 | - | |
| Justin D. Gover | Grant or award | Stock option (right to buy) | 30,000 | $0.00 | - | |
| Justin D. Gover | Grant or award | Stock option (right to buy) | 15,833 | $0.00 | - | |
| Arsani William | Open-market sale | Common Stock | 345,000 | $5.25 | $1.81M | |
| Arsani William | Open-market sale | Common Stock | 217,627 | $5.25 | $1.14M | |
| Deepa Prasad | Open-market sale | Common Stock | 3,806 | $6.27 | $24K |
Design Therapeutics, Inc. (DSGN) had 6 insider filings in the last 90 days, with the most recent on 2026-06-11. The full record for DSGN runs to 10 Form 4 filings, the earliest from 2024-12-19. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of DSGN were filed in the last 90 days.
No insider sales of DSGN were filed in the last 90 days. 3 sales are on record for this company.
This page tracks DSGN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add DSGN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
